1. Home
  2. CNS vs PCVX Comparison

CNS vs PCVX Comparison

Compare CNS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNS
  • PCVX
  • Stock Information
  • Founded
  • CNS 1986
  • PCVX 2013
  • Country
  • CNS United States
  • PCVX United States
  • Employees
  • CNS N/A
  • PCVX N/A
  • Industry
  • CNS Investment Managers
  • PCVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNS Finance
  • PCVX Health Care
  • Exchange
  • CNS Nasdaq
  • PCVX Nasdaq
  • Market Cap
  • CNS 4.2B
  • PCVX 4.4B
  • IPO Year
  • CNS 2004
  • PCVX 2020
  • Fundamental
  • Price
  • CNS $76.74
  • PCVX $35.76
  • Analyst Decision
  • CNS Sell
  • PCVX Strong Buy
  • Analyst Count
  • CNS 4
  • PCVX 10
  • Target Price
  • CNS $77.50
  • PCVX $136.50
  • AVG Volume (30 Days)
  • CNS 187.8K
  • PCVX 1.5M
  • Earning Date
  • CNS 07-17-2025
  • PCVX 08-05-2025
  • Dividend Yield
  • CNS 3.23%
  • PCVX N/A
  • EPS Growth
  • CNS 18.98
  • PCVX N/A
  • EPS
  • CNS 3.06
  • PCVX N/A
  • Revenue
  • CNS $529,174,000.00
  • PCVX N/A
  • Revenue This Year
  • CNS $5.81
  • PCVX N/A
  • Revenue Next Year
  • CNS $12.38
  • PCVX N/A
  • P/E Ratio
  • CNS $25.08
  • PCVX N/A
  • Revenue Growth
  • CNS 8.82
  • PCVX N/A
  • 52 Week Low
  • CNS $68.99
  • PCVX $27.66
  • 52 Week High
  • CNS $110.67
  • PCVX $121.06
  • Technical
  • Relative Strength Index (RSI)
  • CNS 49.59
  • PCVX 57.77
  • Support Level
  • CNS $76.07
  • PCVX $31.79
  • Resistance Level
  • CNS $78.81
  • PCVX $36.89
  • Average True Range (ATR)
  • CNS 2.01
  • PCVX 1.51
  • MACD
  • CNS 0.14
  • PCVX 0.37
  • Stochastic Oscillator
  • CNS 60.80
  • PCVX 77.65

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Share on Social Networks: